Insiders 89bio, Inc.

Equities

ETNB

US2825591033

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-23 pm EDT			5-day change	1st Jan Change
8.18 ^USD	-8.40%		-8.81%	-26.77%

May. 14	89Bio Initiates Phase 3 Enlighten-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis Patients with Compensated Cirrhosis	CI
May. 10	HC Wainwright Adjusts 89bio's Price Target to $29 From $31, Maintains Buy Rating	MT

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

89bio, Inc. Appoints Martin Babler to Its Board of Directors	Apr. 17	CI
89bio Insider Sold Shares Worth $575,153, According to a Recent SEC Filing	Apr. 03	MT
89bio Insider Sold Shares Worth $560,000, According to a Recent SEC Filing	Jan. 03	MT
89Bio, Inc. Announces Board Changes	23-08-15	CI
Insider Sell: 89bio	23-06-07	MT
Insider Sell: 89bio	23-06-05	MT
Insider Sell: 89bio	23-05-11	MT
Insider Sell: 89bio	23-04-06	MT
Insider Buy: 89bio	23-03-30	MT
Insider Sell: 89bio	23-03-03	MT
Spruce Biosciences Names New Chief Medical Officer	22-03-14	MT
89bio, Inc. Appoints Edward Morrow Atkinson to the Board	22-02-24	CI
89bio Announces Appointment of Kathy Laporte to Its Board of Directors	21-11-03	CI
Insider Sell: 89bio	21-10-20	MT
Insider Sell: 89bio	21-09-20	MT
Anat Naschitz to Resign as Member of the Board of 89bio, Inc	21-07-30	CI
89bio Appoints Lota Zoth to Board of Directors	20-06-04	CI
89bio, Inc. Appoints Steven Altschuler, M.D., as Chairman of the Board of Directors	20-03-25	CI
89Bio, Inc. Announces Resignation of Tomer Kariv from the Board of Directors	19-12-16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

As early as today, start finding the best investment opportunities!

Optimize my profits

fermer